AbstractWhile extraocular muscles (EOMs) are affected early in generalized myasthenia gravis (MG), and their treatment responsiveness is similar to nonocular muscles, we have identified an ophthalmoplegic (OP) subphenotype that remains resistant to treatment. This subphenotype of ophthalmoplegic MG (OP‐MG) most commonly affects acetylcholine receptor antibody‐positive cases with juvenile‐onset MG and African genetic ancestry. However, a few OP‐MG cases have been found with MuSK antibodies and triple‐seronegative MG. In a proportion of OP‐MG cases, the EOM treatment resistance manifests from treatment initiation, while in others the EOMs may initially respond until a critical trigger, such as treatment interruption or crisis. The management of OP‐MG is an unmet need. Managing the visual disability may require a surgical or nonsurgical solution. The ideal case selection for surgery and the timing of surgery should be carefully considered. The pathogenesis of OP‐MG remains unknown. A genetic study, using extended whole‐exome sequencing and an “extreme” phenotype sample of OP‐MG versus control MG cases differing only by their EOM responsivity to therapy, discovered several potentially functional OP‐MG risk variants. These variants implicate myogenesis and gangliosphingolipid biosynthesis pathways at the EOM endplates in OP‐MG.